Monopar Therapeutics MNPR

Rank #2460 · Nasdaq · $0.5B market cap

⚠ Going-concern flag — the auditor (BPM LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.

Score

16.3

P/E

-30.2

P/B

84.31

ROE

-278.9%

Op. Margin

–%

Debt Ratio

94%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Poor

P/E -30.2x, P/B 84.31x. Ranks in the top 84% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -278.9%. Ranks in the top 98% of the universe.

Safety ★★★☆☆

Good

Debt ratio 94%. Ranks in the top 37% of the universe.

Growth –

No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2017	$0.0B	$-0.0B	$-0.0B	$0.0B	–	2
2018	$0.0B	$-0.0B	$-0.0B	$0.0B	–	11
2019	$0.0B	$-0.0B	$-0.0B	$0.0B	–	4
2020	–	$-0.0B	$-0.0B	$0.0B	–	10
2021	–	$-0.0B	$-0.0B	$0.0B	–	9
2022	–	$-0.0B	$-0.0B	$0.0B	–	10
2023	–	$-0.0B	$-0.0B	$0.0B	–	17
2024	$0.0B	$-0.0B	$-0.0B	$0.0B	–	17
2025	$0.0B	$-0.0B	$-0.0B	$0.0B	–	94

← See the full screener